Acta Med. 2014, 57: 97-104

https://doi.org/10.14712/18059694.2014.47

Familial Mediterranean Fever

Adem Kucuka, Ilknur Albayrak Gezerb, Ramazan Ucarc, Ali Yavuz Karahand

aNecmettin Erbakan Üniversitesi Romatoloji Bilim Dalı Konya,Turkey
bEğitim ve Araştırma Hastanesi Fiziksel Tıp ve Rehabilitasyon Bölümü Konya, Turkey
cKonya Eğitim ve Araştırma Hastanesi, Dahiliye Kliniği, Konya, Turkey
dDevlet Hastanesi Fiziksel Tıp ve Rehabilitasyon Bölümü Konya, Turkey

Received April 19, 2014
Accepted June 20, 2014

References

1. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011; 7(2): 105–12. <https://doi.org/10.1038/nrrheum.2010.181>
2. Janeway TC, Mosenthal H. Unusual paroxysmal syndrome, probably allied to recurrent vomiting, with a study of nitrogen metabolism. Trans Assoc Am Physicians 1908; 23: 504518.
3. Siegal S. Benign paroxysmal peritonitis. Ann Intern Med 1945; 13: 1–22. <https://doi.org/10.7326/0003-4819-22-1-1>
4. Marmarali A. Garip bir karin sendromu. Turk Tip Cemy Mecm 1946; 12: 436–443.
5. Mamou H, Cattan R. La maladie periodique. Sem Hop Paris 1952; 1062–70.
6. Heller H, Sohar E, Sherf L. Familial Mediterranean fever. AMA Arch Intern Med 1958; 102(1): 50–71. <https://doi.org/10.1001/archinte.1958.00260190052007>
7. Ozkan E. A new approach to the treatment of periodic fever. Med Bull Istanbul 1972; 5: 44–9.
8. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972; 287(25): 1302.
9. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997; 90(4): 797–807.
10. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17(1): 25–31.
11. Onen F. Familial Mediterranean fever. Rheumatol Int 2006; 26(6): 489–96. <https://doi.org/10.1007/s00296-005-0074-3>
12. Fonnesu C, Cerquaglia C, Giovinale M, et al. Familial Mediterranean Fever: a review for clinical management. Joint Bone Spine 2009; 76(3): 227–33. <https://doi.org/10.1016/j.jbspin.2008.08.004>
13. Onen F, Sumer H, Turkay S, Akyurek O, Tunca M, Ozdogan H. Increased frequency of familial Mediterranean fever in Central Anatolia, Turkey. Clin Exp Rheumatol 2004; 22(4 Suppl 34): S31–3.
14. Cobankara V, Fidan G, Turk T, Zencir M, Colakoglu M, Ozen S. The prevalence of familial Mediterranean fever in the Turkish province of Denizli: a field study with a zero patient design. Clin Exp Rheumatol 2004; 22(4 Suppl 34): S27–30.
15. Kisacik B, Yildirim B, Tasliyurt T, et al. Increased frequency of familial Mediterranean fever in northern Turkey: a population-based study. Rheumatol Int 2009; 29(11): 1307–9. <https://doi.org/10.1007/s00296-009-0849-z>
16. Cakir N, Pamuk ON, Dervis E, et al. The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol Int 2012; 32(4): 895–908. <https://doi.org/10.1007/s00296-010-1699-4>
17. Ozdogan H. Sivas’ ın Zara ilçesinde AAA Prevalansı. In: Familial Mediterranean Fever Working Group 2010 Oct 13–17, XI National Congress of Rheumatology, Antalya 2010, p. 234–6.
18. Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nation wide multicenter study. Medicine (Baltimore) 2005; 84(1): 1–11.
19. Cobankara V, Balkarli A. Ailesel Akdeniz Ateşi. Pam Med J 2011; 4(2): 86–98.
20. Dundar M, Emirogullari EF, Kiraz A, Taheri S, Baskol M. Common Familial Mediterranean Fever gene mutations in a Turkish cohort. Mol Biol Rep 2011; 38(8): 5065–9. <https://doi.org/10.1007/s11033-010-0652-7>
21. Yilmaz E, Ozen S, Balci B, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 2001; 9(7): 553–5. <https://doi.org/10.1038/sj.ejhg.5200674>
22. Aladag A, Comlekoglu ME, Dundar M, Gungor MA, Artunc C. Effects of soldering and laser welding on bond strength of ceramic to metal. J Prosthet Dent 2011; 105(1): 28–34. <https://doi.org/10.1016/S0022-3913(10)60187-4>
23. Steiner AA, Chakravarty S, Rudaya AY, Herkenham M, Romanovsky AA. Bacterial lipopolysaccharide fever is initiated via Toll-like receptor 4 on hematopoietic cells. Blood 2006; 107(10): 4000–2. <https://doi.org/10.1182/blood-2005-11-4743> <PubMed>
24. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004; 10(4): 201–22.
25. Creagh EM, O’Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27(8): 352–7. <https://doi.org/10.1016/j.it.2006.06.003>
26. Dinarello CA. Unraveling the NALP-3/IL-1beta inflammasome: a big lesson from a small mutation. Immunity 2004 Mar; 20(3): 243–4. <https://doi.org/10.1016/S1074-7613(04)00055-X>
27. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol 2007; 292(1): 86–98. <https://doi.org/10.1152/ajpregu.00504.2006>
28. Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77(4): 268–97. <https://doi.org/10.1097/00005792-199807000-00005>
29. Guz G, Kanbay M, Ozturk MA. Current perspectives on familial Mediterranean fever. Curr Opin Infect Dis 2009; 22(3): 309–15. <https://doi.org/10.1097/QCO.0b013e328329d15e>
30. Bertin J, DiStefano PS. The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ 2000; 7(12): 1273–4. <https://doi.org/10.1038/sj.cdd.4400774>
31. Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr Top Microbiol Immunol 2006; 305: 127–60.
32. Richards N, Schaner P, Diaz A, et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 2001; 276(42): 39320–9. <https://doi.org/10.1074/jbc.M104730200>
33. Chae JJ, Komarow HD, Cheng J, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003; 11(3): 591–604. <https://doi.org/10.1016/S1097-2765(03)00056-X>
34. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 2006; 103(26): 9982–7. <https://doi.org/10.1073/pnas.0602081103> <PubMed>
35. Yu JW, Wu J, Zhang Z, et al. Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ 2006; 13(2): 236–49. <https://doi.org/10.1038/sj.cdd.4401734>
36. Shohat M, Halpern GJ. Familial Mediterranean fever – a review. Genet Med 2011; 13(6): 487–98. <https://doi.org/10.1097/GIM.0b013e3182060456>
37. Lidar M, Yaqubov M, Zaks N, Ben-Horin S, Langevitz P, Livneh A. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 2006; 33(6): 1089–92.
38. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998; 351(9103): 659–64. <https://doi.org/10.1016/S0140-6736(97)09408-7>
39. Ben-Chetrit E, Ben-Chetrit A. Familial Mediterranean fever and menstruation. BJOG 2001; 108(4): 403–7.
40. Toubi E, Gershoni-Baruch R, Kuten A. Cisplatin treatment triggers familial Mediterranean fever attacks. Tumori 2003; 89(1): 80–1. <https://doi.org/10.1177/030089160308900116>
41. Demirturk L, Ozel AM, Cekem K, Yazgan Y, Gultepe M. Co-existence of Helicobacter pylori infection in patients with Familial Mediterranean Fever (FMF) and the effect of Helicobacter pylori on the frequency and severity of FMF attacks. Dig Liver Dis 2005; 37(3): 153–8. <https://doi.org/10.1016/j.dld.2004.09.027>
42. Ozel AM, Demirturk L, Aydogdu A, et al. Effect of Helicobacter pylori infection and eradication therapy on interleukin-6 levels in patients with Familial Mediterranean Fever Int J Clin Pract 2008; 62(5): 754–61. <https://doi.org/10.1111/j.1742-1241.2006.01098.x>
43. Zadeh N, Getzug T, Grody WW. Diagnosis and management of familial Mediterranean fever: integrating medical genetics in a dedicated interdisciplinary clinic. Genet Med 2011; 13(3): 263–9. <https://doi.org/10.1097/GIM.0b013e31820e27b1>
44. Kees S, Langevitz P, Zemer D, Padeh S, Pras M, Livneh A. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM 1997; 90(10): 643–7. <https://doi.org/10.1093/qjmed/90.10.643>
45. Langevitz P, Zemer D, Livneh A, Shemer J, Pras M. Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol 1994; 21(9): 1708–9.
46. Soylu A, Kasap B, Turkmen M, Saylam GS, Kavukcu S. Febrile myalgia syndrome in familial Mediterranean fever. J Clin Rheumatol 2006; 12(2): 93–6. <https://doi.org/10.1097/01.rhu.0000208635.64537.10>
47. Akse-Onal V, Sag E, Ozen S, et al. Decrease in the rate of secondary amyloidosis in Turkish children with FMF: are we doing better? Eur J Pediatr 2010; 169(8): 971–4. <https://doi.org/10.1007/s00431-010-1158-y>
48. Kukuy O, Livneh A, Ben-David A, et al. Familial Mediterranean fever (FMF) with proteinuria: clinical features, histology, predictors, and prognosis in a cohort of 25 patients. J Rheumatol 2013; 40(12): 2083–7. <https://doi.org/10.3899/jrheum.130520>
49. Ozdogan H, Arisoy N, Kasapcapur O, et al. Vasculitis in familial Mediterranean fever. J Rheumatol 1997; 24(2): 323–7.
50. Girisgen I, Sonmez F, Koseoglu K, Erisen S, Yilmaz D. Polyarteritis nodosa and Henoch-Schonlein purpura nephritis in a child with familial Mediterranean fever: a case report. Rheumatol Int 2012; 32(2): 529–33. <https://doi.org/10.1007/s00296-010-1766-x>
51. Tekin M, Yalcinkaya F, Tumer N, Cakar N, Kocak H. Familial Mediterranean fever and acute rheumatic fever: a pathogenetic relationship? Clin Rheumatol 1999; 18(6): 446–9. <https://doi.org/10.1007/s100670050136>
52. Cattan D, Notarnicola C, Molinari N, Touitou I. Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. Lancet 2000; 355(9201): 378–9. <https://doi.org/10.1016/S0140-6736(99)02134-0>
53. Langevitz P, Livneh A, Zemer D, Shemer J, Pras M. Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum 1997; 27(2): 67–72. <https://doi.org/10.1016/S0049-0172(97)80007-8>
54. Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum 1996; 26(3): 612–27. <https://doi.org/10.1016/S0049-0172(96)80012-6>
55. Gang N, Drenth JP, Langevitz P, et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 1999; 26(4): 890–7.
56. Lachmann HJ, Sengul B, Yavuzsen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45(6): 746–50. <https://doi.org/10.1093/rheumatology/kei279>
57. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis 2002; 61(1): 79–81. <https://doi.org/10.1136/ard.61.1.79> <PubMed>
58. Duzova A, Bakkaloglu A, Besbas N, et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 2003; 21(4): 509–14.
59. Tunca M, Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN. Acute phase response and evolution of familial Mediterranean fever. Lancet 1999; 353(9162): 1415. <https://doi.org/10.1016/S0140-6736(99)00990-3>
60. Balat A, Islek I, Cekmen M, et al. Adrenomedullin and total nitrite levels in children with familial Mediterranean fever. J Paediatr Child Health 2006; 42(5): 240–3. <https://doi.org/10.1111/j.1440-1754.2006.00845.x>
61. Kallinich T, Wittkowski H, Keitzer R, Roth J, Foell D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis 2010; 69(4): 677–82. <https://doi.org/10.1136/ard.2009.114363>
62. Kiraz S, Ertenli I, Arici M, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol 1998; 16(6): 721–4.
63. Notarnicola C, Didelot MN, Seguret F, Demaille J, Touitou I. Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean fever. Genes Immun 2002; 3(1): 43–5. <https://doi.org/10.1038/sj.gene.6363813>
64. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201(9): 1355–9. <https://doi.org/10.1084/jem.20050640> <PubMed>
65. Koklu S, Ozturk MA, Balci M, Yuksel O, Ertenli I, Kiraz S. Interferon-gamma levels in familial Mediterranean fever. Joint Bone Spine 2005; 72(1): 38–40. <https://doi.org/10.1016/j.jbspin.2004.03.011>
66. Basar O, Ozturk MA, Koklu S, et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in familial Mediterranean fever. Joint Bone Spine 2007; 74(1): 52–5. <https://doi.org/10.1016/j.jbspin.2006.02.003>
67. Direskeneli H, Ozdogan H, Korkmaz C, Akoglu T, Yazici H. Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J Rheumatol 1999; 26(9): 1983–6.
68. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40(10): 1879–85. <https://doi.org/10.1002/art.1780401023>
69. Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology 2009; 48(4): 395–8. <https://doi.org/10.1093/rheumatology/ken509>
70. Ben-Chetrit E, Gutman A, Levy M. Dopamine-beta-hydroxylase activity in familial Mediterranean fever. Lancet 1990; 335(8682): 176. <https://doi.org/10.1016/0140-6736(90)90055-A>
71. Courillon-Mallet A, Cauet N, Dervichian M, Launay JM, Cattan D. Plasma dopamine beta-hydroxylase activity in familial Mediterranean fever. Isr J Med Sci 1992; 28(7): 427–9.
72. Pras E, Livneh A, Balow JE, Jr., Kastner DL, Pras M, Langevitz P. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet 1998; 75(2): 216–9. <https://doi.org/10.1002/(SICI)1096-8628(19980113)75:2<216::AID-AJMG20>3.0.CO;2-R>
73. Mor A, Shinar Y, Zaks N, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum. 2005; 35(1): 57–64 <https://doi.org/10.1016/j.semarthrit.2005.02.002>
74. Gershoni-Baruch R, Brik R, Shinawi M, Livneh A. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet 2002; 10(2): 145–9. <https://doi.org/10.1038/sj.ejhg.5200776>
75. Sakallioglu O, Gok F, Kalman S, Gul D, Gokcay E. The phenotype-genotype correlations of FMF patients: a single center study. Rheumatol Int 2006; 26(7): 638–40. <https://doi.org/10.1007/s00296-005-0045-8>
76. Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58(5): 1516–20. <https://doi.org/10.1002/art.23475>
77. Dode C, Andre M, Bienvenu T, et al. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002; 46(8): 2181–8. <https://doi.org/10.1002/art.10429>
78. Sinha A, Waterham HR, Sreedhar KV, Jain V. Novel mutations causing hyperimmunoglobulin D and periodic fever syndrome. Indian Pediatr 2012; 49(7): 583–5. <https://doi.org/10.1007/s13312-012-0099-0>
79. Federici S, Caorsi R, Gattorno M. The autoinflammatory diseases. Swiss Med Wkly 2012; 142: 13602.
80. Padeh S, Brezniak N, Zemer D, et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome. J Pediatr 1999; 135(1): 98–101. <https://doi.org/10.1016/S0022-3476(99)70335-5>
81. Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med 1974; 291(18): 932–4. <https://doi.org/10.1056/NEJM197410312911803>
82. Ozcakar ZB, Yalcinkaya F, Yuksel S, Acar B, Gokmen D, Ekim M. Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 2006; 25(2): 149–52. <https://doi.org/10.1007/s10067-005-1148-z>
83. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994; 37(12): 1804–11. <https://doi.org/10.1002/art.1780371215>
84. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314(16): 1001–5. <https://doi.org/10.1056/NEJM198604173141601>
85. Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 1992; 60(4): 418–22. <https://doi.org/10.1159/000186801>
86. Keven K, Sengul S, Kutlay S, et al. Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: a single-center experience. Transplant Proc 2004; 36(9): 2632–4. <https://doi.org/10.1016/j.transproceed.2004.09.065>
87. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173(3): 699–703. <https://doi.org/10.1084/jem.173.3.699> <PubMed>
88. Seyahi E, Ozdogan H, Masatlioglu S, Yazici H. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clin Exp Rheumatol 2002; 20(26): 43–4.
89. Tunca M, Tankurt E, Akbaylar Akpinar H, Akar S, Hizli N, Gonen O. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 1997; 36(9): 1005–8. <https://doi.org/10.1093/rheumatology/36.9.1005>
90. Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004; 22(34): 37–40.
91. Calguneri M, Apras S, Ozbalkan Z, Ozturk MA, Ertenli I, Kiraz S. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004; 22(34): 41–4.
92. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008; 75(4): 504–5. <https://doi.org/10.1016/j.jbspin.2008.04.001>
93. Onat AM, Ozturk MA, Ozcakar L, et al. Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever. Tohoku J Exp Med 2007; 211(1): 9–14. <https://doi.org/10.1620/tjem.211.9>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive